Answers are grounded in this paper and cite their sources.
Reliable triage methods are essential in cervical cancer screening to avoid overtreatment. DNA methylation markers offer an objective molecular readout with potential to keep false-positive rates low. We evaluated the GynTect ® DNA methylation assay as a triage marker in cervical samples from women with abnormal cytology, in comparison with the p16/Ki-67 Dual Stain test CINtec Plus ® . Surplus liquid-based cytology samples from 1,000 women with cytology ≥ PAP III (Low-Grade Squamous Intraepithelial Lesion = LSIL, or worse) were tested with GynTect ® (markers: ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671). cobas ® HPV and p16/Ki-67 Dual Stain (CINtec Plus ® ) results were available for all samples; histopathology was available for a subset of 601 samples. Positivity rates with 95% confidence intervals were calculated using the Wilson score method. Overall GynTect positivity was 27.7% versus 88.3% for p16/Ki-67 Dual Stain. Methylation positivity correlated with cytological severity: 17.0% in LSIL, 30.2% in moderate High-Grade Squamous Intraepithelial Lesion HSIL, and 65.0% in the PAP IV group (high-grade SIL/AIS and HSIL suspicious for invasion). Among HPV16/18-positive samples, 38.4% were GynTect-positive versus 94.8% p16/Ki-67 Dual Stain-positive. By histopathology, GynTect positivity was 15.0% (CIN I), 27.0% (CIN II), and 56.5% (CIN III); all four cancer cases were GynTect- and p16/Ki-67 Dual Stain-positive. Of 191 GynTect-positive cases with histopathology, 73% had CIN II or CIN III. GynTect positivity (27.7%) was significantly lower than p16/Ki-67 Dual Stain positivity (88.3%), with a statistically significant monotonic trend across increasing cytological severity (Cochran-Armitage trend test, p < 0.001) and histopathological categories ( p < 0.001). All four histologically confirmed carcinomas were GynTect-positive. These findings are consistent with a potential role for GynTect in selective triage after abnormal cytology, with lower positivity rates suggesting higher selectivity for high-grade disease compared with p16/Ki-67 Dual Stain. Prospective validation in primary HPV-screening triage populations is required to determine whether this translates into clinical benefit.
No takes yet. Share an insight, caveat, or question.
Zeiser et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: